Compare Jabil Inc (JBL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Viatris Inc — how do they compare? Jabil Inc trades at $306.28 (market cap $31.35B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Jabil Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Viatris Inc for 57 Days on average.
| JBL | VTRS | |
|---|---|---|
Market Cap | $31.35B | $20.03B |
Volume | 1,337,978 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $385.50 | $18.27 |
52-Week Low | $192.49 | $9.74 |
Typical Hold Time | 23 Days | 57 Days |
Enterprise Value | $33.63B | $32.15B |
Dividend Yield | 0.11% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $306.28, up 2.27% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q4 2026 earnings, beating estimates with EPS of $4.40, driven by AI infrastructure demand. Revenue for fiscal 2026 was $29.80 billion, with net income of $657 million. Analyst consensus is bullish with a $434.75 price target, implying significant upside. Recent news highlights AI-led growth prospects for fiscal 2027.
Outlook is positive based on robust earnings and AI-driven guidance, but risks include high valuation multiples and market volatility. The stock offers growth potential from expanding AI infrastructure demand, though investors should monitor execution on projected 24% revenue growth for fiscal 2027 and competitive pressures in the electronics manufacturing sector.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
